Paramount
Paramount
Paramount, California, United States7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC | Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, constipation disorder | Recruiting | Phase 2 | 2026-10-07 | NCT07723924 | |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Chronic Cough, Cough, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Signs and Symptoms, Respiratory, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-07-14 | NCT05600777 | |
| Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough | Refractory or Unexplained Chronic Cough | Active, not recruiting | Phase 2 | 2026-06-11 | NCT06504446 | |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age | DNA Virus Infections, Herpesviridae infectious disease, Infections, Varicella Zoster Virus Infection, chickenpox, viral infectious disease | Recruiting | Phase 3 | 2026-05-29 | NCT06740630 | |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Tumor Virus Infections, hematologic disorder, immune system disorder, immunoproliferative disorder, infectious mononucleosis, leukocyte disorder, lymphatic system disorder, lymphoproliferative syndrome, viral infectious disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT05164094 | |
| Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Pneumococcal Immunization | Active, not recruiting | Phase 3 | 2026-04-13 | NCT06824194 | |
| Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, pneumococcal infection, streptococcal infection | Active, not recruiting | Phase 3 | 2025-10-06 | NCT06838000 |